Actimed gets back rights to wasting disease drug, ending $126M deal with Faraday

Posted inBiotechnology

Actimed Therapeutics has brought the full rights to its wasting disease drug back in-house, securing “strategic control” over the asset but losing out on a shot at over $120 million in biobucks.